Key result
Early initiation of vericiguat was explored in four patient profiles with worsening heart failure, suggesting potential benefits in reducing residual risk.
Why the study?
Despite effective current heart failure treatments, there is a need to reduce residual cardiovascular events and hospitalizations, and early vericiguat initiation may benefit worsening heart failure.
Does early initiation of vericiguat provide benefits in patients with worsening heart failure?
Does early initiation of vericiguat provide benefits in patients with worsening heart failure?
Early initiation of vericiguat may be beneficial in specific profiles of patients with worsening heart failure.
Answers are grounded in this paper and cite their sources.
May support early vericiguat in select worsening HF profiles; hypothesis-generating case series leaves confirmation to prospective trials.
Heart failure, a condition that can result in a large number of hospitalizations each year, can result in worsening heart failure. Although current treatments for heart failure are effective, there is a need to reduce the residual risk of cardiovascular events and hospitalizations. Vericiguat, a sGC stimulator, may be a promising treatment option for heart failure with signs of worsening, and early initiation of this therapy may be beneficial in certain patient profiles. This article explores the potential benefits of early Vericiguat initiation in four patient profiles with worsening heart failure.
No takes yet. Share an insight, caveat, or question.
Kaul et al. (2024) conducted a review in Worsening heart failure (n=4). Vericiguat was evaluated. Early initiation of vericiguat was explored in four patient profiles with worsening heart failure, suggesting potential benefits in reducing residual risk.
Synapse has enriched 10 related papers. Consider them for comparative context: